Cyberkinetics Presents Seven-Month Results from Pilot Study of BrainGate(TM) Neural Interface System at ICORR Meeting.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB - CYKN) reported ongoing pilot clinical trial progress of the Company's BrainGate(TM) Neural Interface System (BrainGate System) in a poster presentation titled, "Case Study: Reliability of Multi-Electrode Array in the Knob Area of Human Motor Cortex Intended for a Neuromotor Prosthesis Application." The poster was presented on June 29, 2005, at the 9th International Conference on Rehabilitation Robotics (ICORR) hosted by the Rehabilitation Institute of Chicago. ICORR is a series of international conferences focused on advances in rehabilitative robotic devices designed to assist people with moderate to severe motor impairments. Cyberkinetics' BrainGate System is being developed to enable those with motor impairments resulting from a variety of causes to control a wide range of external devices.

Interim results detailed in Cyberkinetics' ICORR poster presentation cover seven months of its ongoing pilot trial of its BrainGate System in people with severe paralysis. In the current study, researchers demonstrated the reliability of the BrainGate System to detect the activity of neurons over extended periods of time. Researchers also reported on the use of newly developed software to automatically sort neuronal signals in approximately two minutes, a significant reduction over the 30-minute time span previously required for technicians to manually sort neuronal signals. This automated process appeared to extract data from more neurons than were previously extracted manually. The automated software element is a critical building block for the Company's M*Power(TM) Controller System (M*Power(TM) Controller).

"Our participation in the ICORR meeting is an important step as we look to the future incorporation of limb-movement technologies in our clinical trial planning," commented John P. Donoghue, Ph.D., Cyberkinetics' founder and Chief Scientific Officer. "As this poster details, we have gained extensive knowledge based upon months of experience from a person with severe paralysis using our BrainGate System."

Ultimately, Cyberkinetics' M*Power Controller is intended to enable users of the system to readily perform a wide variety of daily activities that are currently beyond their abilities, extending from control of everyday devices to as far as restoration of limb movement and communication. For example, a motor impaired individual could, by thought alone, use the M*Power Controller System to control a hybrid cell phone/computer, such as an iPAQ, to make and receive telephone calls, to control light switches or a television, and to access the internet and communicate via e-mail. Cyberkinetics expects the improved M*Power Controller System, in the future, to be easier for patients and their families because it would enable them to use the BrainGate System on a routine basis without reliance on a specialized technician.

Results from the current study demonstrate that:

--Cyberkinetics' BrainGate System detects, transmits and analyzes the firing of individual neurons in the patient's motor cortex;

--The patient is able to modulate neural activity by imagining arm and hand movement; and

--The BrainGate System translates neural signals into a computer cursor controller that has enabled the study participant to perform activities of daily living, including control of computer software, as well as reaching, grasping and moving objects through a robotic limb.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, a leader in brain interface technology, is developing products to treat nervous system diseases and disorders by bringing together advances in neuroscience, computer science and engineering. Cyberkinetics' products are based on over ten years of technology development and cutting-edge neuroscience research at leading academic institutions such as Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. Cyberkinetics is publicly traded on the Over the Counter Bulletin Board under the ticker symbol CYKN. The Company is headquartered in Foxborough, Massachusetts and conducts engineering and research in Salt Lake City, Utah.

Cyberkinetics' flagship product, the BrainGate(TM) Neural Interface System, is being designed to give severely paralyzed individuals, as well as individuals with motor impairment from a variety of causes, a long-term, direct brain-computer interface for the purpose of communication and control of a computer, assistive devices, and, ultimately, limb movement. Patients are currently being enrolled into a pilot clinical trial to test the BrainGate(TM) System's safety and feasibility.

Cyberkinetics has received FDA clearance to market the NeuroPort(TM) System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity. The NeuroPort System can contribute to the diagnosis and treatment of neurological conditions in patients who have undergone craniotomy by providing neurologists and neurosurgeons a new resource to detect, transmit and analyze neural activity.

Reprints of the ICORR poster, digital photos and illustrations of the BrainGate System are available at www.cyberkineticsinc.com.

Forward Looking Safe Harbor Statement:

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.